blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2079448

EP2079448 - IMPROVED RELEASE OF STATINS IN THE INTESTINE [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  05.04.2013
Database last updated on 14.06.2024
Most recent event   Tooltip05.04.2013Application deemed to be withdrawnpublished on 08.05.2013  [2013/19]
Applicant(s)For all designated states
Dexcel Pharma Technologies Ltd.
P.O. Box 50
38100 Hadera / IL
[2009/30]
Inventor(s)01 / PENHASI, Adel
53/15 Rabinovich Street
58671 Holon / IL
02 / GOMBERG, Maxim
420/19 Neve Jakov
97350 Jerusalem / IL
 [2009/30]
Representative(s)Straus, Alexander, et al
Patentanwälte
Becker, Kurig, Straus
Bavariastrasse 7
80336 München / DE
[N/P]
Former [2009/30]Straus, Alexander, et al
Patentanwälte Becker, Kurig, Straus Bavariastrasse 7
80336 München / DE
Application number, filing date07827194.709.10.2007
[2009/30]
WO2007IL01220
Priority number, dateUS20060850255P10.10.2006         Original published format: US 850255 P
[2009/30]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2008044236
Date:17.04.2008
Language:EN
[2008/16]
Type: A2 Application without search report 
No.:EP2079448
Date:22.07.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 17.04.2008 takes the place of the publication of the European patent application.
[2009/30]
Search report(s)International search report - published on:EP26.06.2008
ClassificationIPC:A61K9/20
[2009/30]
CPC:
A61K9/2886 (EP,US); A61K9/2013 (EP,US); A61K9/2018 (EP,US);
A61K9/2027 (EP,US); A61K9/2054 (EP,US); A61K9/282 (EP,US);
A61K9/284 (EP,US); A61K9/2866 (EP,US); A61P9/10 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/30]
TitleGerman:VERBESSERTE FREISETZUNG VON STATINEN IM DARM[2009/30]
English:IMPROVED RELEASE OF STATINS IN THE INTESTINE[2009/30]
French:LIBÉRATION AMÉLIORÉE DE STATINES DANS L'INTESTIN[2009/30]
Entry into regional phase07.04.2009National basic fee paid 
07.04.2009Designation fee(s) paid 
07.04.2009Examination fee paid 
Examination procedure07.04.2009Amendment by applicant (claims and/or description)
07.04.2009Examination requested  [2009/30]
20.07.2009Despatch of a communication from the examining division (Time limit: M06)
28.01.2010Reply to a communication from the examining division
29.06.2012Despatch of a communication from the examining division (Time limit: M04)
10.11.2012Application deemed to be withdrawn, date of legal effect  [2013/19]
19.12.2012Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2013/19]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  20.07.2009
Fees paidRenewal fee
26.10.2009Renewal fee patent year 03
12.10.2010Renewal fee patent year 04
25.10.2011Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
31.10.201206   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO9930692  (ANDRX PHARMACEUTICALS INC [US]) [X] 1-57 * page 9, lines 3-19; example 1; claims 1-12 *;
 [X]WO0134123  (ANDRX CORP [US], et al) [X] 1-57 * pages 16-17; example 1; table 1 *;
 [X]WO0074655  (PERIO PROD LTD [IL], et al) [X] 1,3,8-10,17-47,49 * page 33; claims 1-19,35 *;
 [X]EP1021171  (PERIO PROD LTD [IL]) [X] 1,3,8-10,17-47,49 * paragraphs [0093] , [0102]; claims 1,4,5,8 *;
 [A]EP1191926  (ASTRAZENECA AB [SE]) [A] 1-57 * claims 1-18 *;
 [A]WO9725979  (PERIO PROD LTD [IL]) [A] 1-57 * pages 38-40; claims 1-20 *;
 [A]EP0210540  (FUJISAWA PHARMACEUTICAL CO [JP]) [A] 1-57 * column 1, lines 4-14; figure 1 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.